[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ottawa Heart Institute Research Corporation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":619},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,40,0,25,[9,43,68,93,116,143,170,196,219,247,274,302,330,352,375,398,421,442,463,487,509,529,546,573,596],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053589","predicting-development-of-scaf-in-device-patients-100053589",false,"NCT02808260","Predicting Development of SCAF in Device Patients","Predicting Development of Sub-Clinical Atrial Fibrillation in Device Patients","Inclusion Criteria:\n\n• Dual chamber permanent pacemaker or defibrillator implanted within previous 10 years\n\nExclusion Criteria:\n\n* Clinical atrial fibrillation documented by surface ECG (12 lead ECG, Telemetry, Holter)\n* Participants considered by the investigator to be unsuitable for the study for the following reason: life expectancy less than 2 years due to concomitant disease\n* Participants who are pregnant or breast-feeding\n* Congenital heart disease\n* Inherited arrhythmia syndrome, i.e. Brugada, long QT interval","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","Atrial fibrillation (AF) often starts with short episodes of rapid irregular heartbeats that are only detected by implanted pacemakers or defibrillators. Usually people don't know that they have these episodes. Over time, these episodes can happen more often and last for longer periods. In some people, the heart eventually remains permanently in a fast irregular rhythm, known as atrial fibrillation. This condition can lead to strokes and blood clots. If physicians could detect atrial fibrillation at a very early stage they could treat people early and possibly prevent the condition from becoming permanent. People with implanted devices allow a unique opportunity to constantly monitor the heart rhythm so investigators can detect any irregularities immediately.\n\nInvestigators don't know which people are at risk of developing short episodes of fast irregular heartbeats that can lead to atrial fibrillation. The purpose of this study is to find out if there are proteins or chemical changes in the blood that can predict the risk of developing atrial fibrillation. These chemical changes, also known as biomarkers, may also be able to give investigators other clues about atrial fibrillation.",[25],"Atrial Fibrillation",[27,28,29],"sub-clinical atrial fibrillation","biomarkers","implanted pacemaker or defibrillator","RECRUITING","2026-07-09",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2022-09-01",{"date":38,"type":21},"2034-09",{"name":40,"class":41},"Ottawa Heart Institute Research Corporation","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100640787","transition-and-transfer-of-congenital-heart-disease-care-from-pediatrics-to-adulthood-100640787","NCT07585175","Transition and Transfer of Congenital Heart Disease Care From Pediatrics to Adulthood","Transition and Transfer of Congenital Heart Disease Care From Pediatrics to Adulthood.","Inclusion Criteria:\n\n* All new patients with congenital heart disease referred from the pediatric hospital and the community\n\nExclusion Criteria:\n\n* None",{"count":51,"type":21},200,"2 Years","Adults with congenital heart disease (CHD) are a growing patient population in need of ongoing specialized care. Lapses in appropriate transition and transfer processes from childhood to adulthood in CHD care can lead to loss in follow up, late detection of new or evolving cardiac complications and negative patient outcomes. Therefore, it is vital that a robust transition and transfer process is established. Through a retrospective study completed recently at the University of Ottawa Heart Institute (UOHI) we have shown that the average wait time to be assessed by an adult congenital heart disease (ACHD) specialist is about 10 months and within this wait period 1 in 8 ACHD patients have a decline in their health.\n\nThe goal of this study is to specifically reduce negative patient outcomes during this wait period. We aim to achieve this by (i) establishing a program to ensure early detection of patients at risk of deterioration and (ii) providing additional support to these patients. The program is designed to have a multipronged approach including tools to disseminate concise patient specific information among care providers, maintain open line of communication with patients on the waitlist and promote patient education.\n\nWe plan to improve our transition care by creating a multi-pronged transfer program specifically for patients on the wait list composed of a nurse check in, creation of a diagnosis summary, education day and combined pediatric cardiology\u002FACHD handover videocall (described below). This program is planned as part of our care pathway and will be offered to all patients on the wait list. We intend to document the efficacy of this transition program to improve transition care by assessing patient reported outcomes and clinical outcomes of the patients who consent to complete additional questionnaires.\n\nThe multi-pronged program will include the following:\n\n1. ACHD nurse check-in (patient check-in via phone call or zoom from the ACHD nurse within 1 month of receiving referral) - allows early establishment of clinical relationship with the patient, screen for risk factors for deterioration and provision of ACHD clinic contact information to enable open line of communication. Patients considered at risk for deterioration on the wait-list based on this check-in conversation will be triaged for a more urgent first consult at the ACHD clinic.\n2. Quick glance diagnosis summary (Electronic on Epic MyChart) - will be created during nurse check in and will be used to disseminate concise patient specific information among health care workers and acts as a reference for the patients.\n3. Organization of an ACHD patient education day (half day hybrid event every 6 months) - allows formal introduction to the ACHD team, provides information session on ACHD care and lowers patients' threshold to inform the ACHD team in case of clinical deterioration.\n4. Combined pediatric cardiology and ACHD handover video call at time of transfer - allows effective and efficient handover of patient care from pediatric to adult care and facilitates the coordination of care during the transfer period.\n\nThese four components of the program work together to provide tools to disseminate concise patient specific information among care providers, maintain open line of communication with patients on the waitlist and promote patient education.",[55],"Congenital Heart Disease (CHD)",[57,58,59],"Adult Congenital Heart Disease","Transfer of care","Transition of care","2026-06-30",{"date":62,"type":34},"2026-07-02",{"date":64,"type":34},"2024-06-01",{"date":66,"type":21},"2026-12-31",{"name":40,"class":41},{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100630385","endocrine-disruption-menopause-and-poor-sleep-in-women-with-type-2-diabetes-effects-on-cardiovascular-health-100630385","NCT07486986","Endocrine Disruption, Menopause, and Poor Sleep in wOmen With Type 2 Diabetes: Effects on Cardiovascular Health","EMPOWER","Inclusion Criteria:\n\n* Female Sex\n* Age range 48-58 years\n* In menopausal transition phase (pre-menopause or peri-menopause)\n* Diagnosis of Type 2 Diabetes Mellitus\n* Have access to and regularly use a smartphone with internet access\n\nExclusion Criteria:\n\n* Male Sex\n* Currently Pregnant\n* Prior history of total hysterectomy or bilateral oophorectomy\n* Prior diagnosis of any of the following:\n\nCoronary Vascular Disease (CVD) including coronary heart disease, heart failure, congenital heart disease stroke\u002Ftransient ischemic attack, valvular heart disease, peripheral vascular disease, aortapathy, atrial fibrillation or flutter, other CVD.\n\n\\- Untreated serious mental illness (e.g, untreated psychosis).","FEMALE","48 Years","58 Years",{"count":79,"type":21},381,"EMPOWER aims to determine the overall effect of menopause and sleep disruption on cardiac remodeling in women with type 2 diabetes.",[82,83,84],"Menopause","Sleep Disruption","T2DM","NOT_YET_RECRUITING",{"date":87,"type":34},"2026-07-01",{"date":89,"type":21},"2026-09",{"date":91,"type":21},"2032-12",{"name":40,"class":41},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":42},"100621241","mental-health-after-dexmedetomidine-for-electrical-storm-100621241","NCT07368062","Mental Health After Dexmedetomidine for Electrical Storm","Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm: Outpatient Follow-up of Mental Health INDices (SDATE OF MIND)","Inclusion Criteria:\n\n* Patients admitted to an intensive care unit with a diagnosis of electrical storm within the preceding 6 months\n* Previous participants in the SEDATE trial (NCT06281977)\n\nExclusion Criteria:\n\n\\- None",{"count":101,"type":21},70,"The goal of the research study is to measure mental health and quality of life indices of individuals treated for electrical storm (ES). The consequences of being admitted to an intensive care unit (ICU) with electrical storm as well as the treatments patients would have received, are currently not well understood. Understanding the mental health burden of these treatments among survivors can provide insights into how to improve care.\n\nThis is a study consisting of patients who participated in the SEDATE trial (dexmedetomidine vs usual standard of care to treat ES in the ICU). Patients who consent to participate in this study will be asked to complete a set of questionnaires 3-6 months after their ICU admission. The purpose of the questionnaires is to measure indices of mental health and health-related quality of life. Each questionnaire will take about 5-15 minutes to complete.\n\nIf patients have a scheduled follow-up at the University of Ottawa Heart Institute, a member of the research team will meet with them during their clinic visit to complete the questionnaires. Otherwise, they can be completed over the telephone.",[104],"Mental Health",[106,107,108,109],"Electrical storm","Ventricular tachycardia","Dexmedetomidine","Mental health",{"date":87,"type":34},{"date":112,"type":34},"2025-03-15",{"date":114,"type":21},"2028-06",{"name":40,"class":41},{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":125,"phases":126,"briefSummary":128,"conditions":129,"keywords":133,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":42},"100585813","phase-3-dapagliflozin-for-long-covid-syndrome-100585813","NCT06907251","Dapagliflozin for Long COVID Syndrome","DALCO","Inclusion Criteria:\n\n* 18 years of age or older and willing and able to provide informed consent\n* Patients with a history of positive COVID-19 test (polymerase chain reaction or rapid test) or have been diagnosed with COVID-19 by a health care provider.\n* New or persistent symptoms at least 12 weeks from infection and present for at least 8 weeks that is not explained by an alternative diagnosis (64).\n* Women of childbearing potential (WOCBP) who, if sexually active, are willing to use to use at least one highly effective methods of contraception throughout the study.\n\nExclusion Criteria:\n\n* History of diabetes\n* Prior heart failure\n* Weight loss treatment with glucagon-like peptide-1 receptor agonists (e.g. liraglutide, semaglutide)\n* Pregnancy or planned pregnancy in the next 12 months. We will ask WOCBP about the possibility of pregnancy at the time of screening and if so, then pregnancy testing will be offered. If testing is declined in this instance, then they will be excluded from the study.\n* Women who are breastfeeding\n* Severe renal impairment (eGFR\\\u003C30mL\u002Fmin1.73m2)\n* Known history of allergy or hypersensitivity to dapagliflozin\n\nExclusion for optional MRI portion of the protocol:\n\n\\- Any contraindication to MRI",{"count":124,"type":21},192,"INTERVENTIONAL",[127],"PHASE3","This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.",[130,131,132],"COVID - 19","Long COVID Syndrome","SARS CoV-2",[134,135,136],"Covid-19","Long Covid syndrome","sars cov-2",{"date":87,"type":34},{"date":139,"type":21},"2026-09-01",{"date":141,"type":21},"2029-06-30",{"name":40,"class":41},{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":125,"phases":153,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},"100449718","qol-improvement-after-cardioversion-of-persistent-af-qol-cafrct-100449718","NCT05136131","QOL Improvement After Cardioversion of Persistent AF (QOL-CAFRCT)","Quality of Life Improvement After Cardioversion of Persistent AF - A Randomized Sham-Controlled Clinical Trial","QOL-CAFRCT","Inclusion Criteria:\n\n* Patients age ≥ 18 years\n* Persistent atrial fibrillation\n* Unknown symptom burden related to AF\n\nExclusion Criteria:\n\n* Known left-atrial appendage thrombus\n* Prior catheter or surgical ablation for AF\n* Intolerance or contraindication to Amiodarone\n* Contraindication to appropriate anticoagulation\n* Patient is included in another randomized clinical trial\n* Patient is unable or unwilling to provide informed consent\n* Patient with a history of noncompliance with medical therapy\n* Patient does not meet all of the above listed inclusion criteria\n* Pregnancy (all women of child bearing age and potential will have a negative BHCG test before enrolment)\n* Breastfeeding\n* Patients for whom the investigator believes that the trial is not in the interest of the patient",{"count":152,"type":21},100,[154],"NA","Atrial fibrillation (AF) is a type of irregular heart rhythm due to electrical signal disturbances of the heart. It is a very common arrhythmia and the risk of developing AF increases with age and with other risk factors such as diabetes, high blood pressure, and underlying heart disease. The main complications of AF are heart failure and stroke. However, studies have shown that restoration of normal rhythm does not reduce these complications. Rather, these complications are mitigated by controlling the heart rate and using blood thinners to prevent stroke. Symptoms secondary to AF can occur due to the irregular heart rate and poor contraction in the atria, the top chambers of the heart. These symptoms include shortness of breath, fatigue, reduced exercise tolerance, and palpitations. Restoring sinus rhythm can sometimes alleviate these symptoms. Given that studies to date have not shown a difference in hard clinical endpoints between rate and rhythm control strategies, the decision to proceed with rhythm control depends on the patient symptom burden.\n\nRhythm control strategies in patients with persistent AF include cardioversion back to sinus rhythm with long-term recurrence prevention via anti-arrhythmic drugs (AADs) or catheter ablation. However, many studies of these procedures omit a sham placebo control arm. No atrial fibrillation procedural intervention has been compared to a sham procedure. The cardioversion procedure can easily be compared to a \"sham\" alternative, as it is non-invasive with an expected response within days-to-weeks. Thus, a cardioversion versus \"sham\" cardioversion trial will allow us to truly assess the impact of a rhythm-control strategy on QOL. It is hypothesized that cardioversion of atrial fibrillation leads to significant improvement in quality of life (QOL) compared to sham cardioversion.\n\nUnderstanding the true QOL impact of sinus rhythm restoration in patients with persistent AF is of significant importance in guiding strategies for the management of AF. Hence, by evaluating what the true effect of cardioversion on QOL in this blinded study, we can better understand the role of medical management and AF ablation in our patients and assess resource allocation to these procedures.",[25],[158,159,160,161,162],"Quality of life improvement","Electrical cardioversion","Sham cardioversion","Rhythm control","Placebo",{"date":87,"type":34},{"date":165,"type":34},"2023-02-10",{"date":167,"type":21},"2027-05",{"name":40,"class":41},2,{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":125,"phases":180,"briefSummary":181,"conditions":182,"keywords":185,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":195},"100331323","phase-3-cardiac-sarcoidosis-randomized-trial-100331323","NCT03593759","Cardiac Sarcoidosis Randomized Trial","Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial","CHASM-CS-RCT","Inclusion Criteria:\n\n(i) Cardiac sarcoidosis presenting with one or more of the following clinical findings:\n\n* advanced conduction system disease (defined as Mobitz II AV block or third degree AV block)\n* significant sinus node dysfunction (defined as average HR less than 40bpm when awake and\u002For sustained atrial arrhythmias)\n* non- sustained or sustained ventricular arrhythmia\n* left ventricular dysfunction (LVEF \\\u003C 50%)\n* right ventricular dysfunction (RVEF \\\u003C 40%)\n\nAND\n\n(ii) No alternative explanation for clinical features\n\nAND\n\n(iii) Nuclear Imaging within six-months of enrollment consisting of FDG-PET scan with FDG uptake suggestive of active CS and myocardial perfusion imaging\n\nAND ONE OR BOTH OF FOLLOWING\n\n(iv) Positive biopsy for Sarcoid (either EMB or extra-cardiac)\n\n(v) CT Chest showing features consistent with pulmonary sarcoidosis and\u002For mediastinal and\u002For hilar lymphadenopathy\n\nExclusion Criteria:\n\n1. Current or recent (within two months) non-topical treatment for sarcoidosis\n2. Current Oral\u002FIV treatment of duration greater than 5 days\n3. Currently taking Methotrexate or Prednisone for another health condition\n4. Intolerance or contra-indication to Methotrexate or Prednisone\n5. Patient does not meet all of the above listed inclusion criteria\n6. Patient is unable or unwilling to provide informed consent\n7. Patient is included in another randomized clinical trial\n8. Patient has a contraindication to PET imaging or is unlikely to tolerate due to severe claustrophobia\n9. Pregnancy (all women of child bearing age and potential will have a negative BHCG test before enrollment)\n10. Breastfeeding\n11. Women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception throughout the study\n12. Patients for whom the investigator believes that the trial is not in the interest of the patient",{"count":179,"type":21},194,[127],"Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)\u002FMethotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated.\n\nThe Investigators hypothesize that low dose Prednisone(or Prednisolone)\u002FMethotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than standard dose Prednisone(or Prednisolone).",[183,184],"Cardiac Sarcoidosis","Sarcoidosis",[183,186,187],"Prednisone (or Prednisolone)","Methotrexate","2026-06-29",{"date":62,"type":34},{"date":191,"type":34},"2019-01-15",{"date":193,"type":21},"2026-12",{"name":40,"class":41},31,{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":207,"conditions":208,"keywords":209,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":218},"100169296","cardiac-sarcoidosis-multi-center-prospective-cohort-100169296","NCT01477359","Cardiac Sarcoidosis Multi-Center Prospective Cohort","Cardiac Sarcoidosis Multi-Center Prospective Cohort Study","CHASM-CS","Inclusion Criteria:\n\nTo diagnose Clinically Manifest CS all following criteria must be met:\n\n(i) Positive biopsy\\* for Sarcoid (either EMB or extra-cardiac) AND\u002FOR (ii) CT Chest highly suggestive of pulmonary sarcoidosis AND (iii) one or more of the following clinical features:\n\n* advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)\n* non- sustained or sustained ventricular arrhythmia\n* ventricular dysfunction (LVEF \\\u003C 50% and\u002For RVEF \\\u003C 40%) AND (iv) No alternative explanation for clinical features AND (v) FDG-PET suggestive of active CS\n\nTo diagnose clinically silent CS all of the following criteria must be met\n\n(i) Biopsy proven extra-cardiac sarcoidosis\n\nAND\u002FOR (ii) CT Chest highly suggestive of pulmonary sarcoidosis\n\nAND (iii) CMR suggestive of cardiac sarcoidosis\n\nAND (iv) Does not have criteria for clinically manifest CS ie. should not have any of following\n\n* advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)\n* non- sustained or sustained ventricular arrhythmia\n* ventricular dysfunction (LVEF \\\u003C 50% and\u002For RVEF \\\u003C 40%)\n\nPatients with negative CMR will be designated as 'extra-cardiac sarcoidosis with no evidence of CS' and followed as control\n\nExclusion Criteria:\n\n* unable or unwilling to provide informed consent\n* patients who are pregnant or lactating\n* patients with known claustrophobia\n* age \\\u003C 18 years","99 Years",{"count":206,"type":21},1500,"Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations. Thus many patients with clinically important CS are going un-diagnosed. A study from Finland showed that missing the diagnosis of CS in these patients' leads to significant mortality and morbidity.\n\nThere are no published clinical consensus guidelines on treatment of CS. Corticosteroid therapy is advocated by most experts. This is based on very modest data from small retrospective observational studies using variable definitions of clinical response. The effect of corticosteroid treatment on the clinical course of CS has not been studied in prospective studies and will be one of the aims of this project. Recent physician surveys regarding CS, in Canada and the US, found that current clinical practice varies widely. The 2008 American College of Cardiology\u002FAmerican Heart Association\u002FHeart Rhythm society guidelines recommend implantation of a defibrillator (Class IIa recommendation) to prevent sudden cardiac death. The most recent Canadian device therapy guidelines do not mention CS.\n\nA multi-center collaborative approach to study CS is greatly needed.\" The investigators propose exactly that i.e. a multi-center prospective cohort to start to answer clinical questions. The investigators have formed the CANADIAN CARDIAC SARCOIDOSIS RESEARCH GROUP. The group includes respirologists with an interest in sarcoidosis, cardiac electrophysiologists, cardiac imaging specialists with extensive experience in imaging of sarcoidosis and biostatisticians. The research will be in two phases; a registry of current diagnostic approaches, treatment and prognosis, and a randomized clinical trial of the effect of corticosteroid treatment on the clinical course of cardiac sarcoidosis.",[183],[184],"2026-06-23",{"date":212,"type":34},"2026-06-24",{"date":214,"type":34},"2012-08",{"date":216,"type":21},"2035-12",{"name":40,"class":41},14,{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":125,"phases":228,"briefSummary":229,"conditions":230,"keywords":233,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":246},"100593131","left-atrial-imaging-prior-to-cardioversion-leveraging-computed-tomography-to-rule-out-thrombus-in-the-emergency-department-la-clotted-100593131","NCT07002450","Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Department (LA CLOTTED)","LA CLOTTED","Inclusion Criteria:\n\n1. Age ≥18 years old; and\n2. Primary symptomatic AF without a reversible underlying cause (e.g. sepsis, pneumonia, pulmonary embolism, hyperthyroidism)\n3. LA imaging required before cardioversion according to local clinical practice guidelines\n\nExclusion Criteria:\n\n1. Patients with an indication for emergency cardioversion (e.g. hemodynamic instability (systolic blood pressure\\\u003C90mmHg or signs of shock), cardiac ischemia (ongoing severe chest pain or marked ST depression on ECG \\>2mm), or pulmonary edema (significant dyspnea, crackles, or hypoxia)); or\n2. Contraindication to CCT (renal insufficiency (eGFR\\\u003C 45ml\u002Fmin\u002F1.73m2), allergy to intravenous contrast agents, pregnancy (contraindications to radiation exposure), or inability to perform 20-second breath-hold)",{"count":227,"type":21},190,[154],"The goal of this randomized clinical trial is to learn whether patients with symptomatic atrial fibrillation or atrial flutter (AF) who require heart imaging to rule out a blood clot before cardioversion would benefit from cardiac computed tomography angiography (CCT) in the emergency department (ED) compared to current standard of care management.\n\nThis will be a multicenter trial evaluating whether CCT-facilitated cardioversion in the ED reduces hospital admission, reduces repeat presentations to hospital and improves patient quality of life compared to the current standard of care.\n\nParticipants will undergo CCT-facilitated cardioversion or be treated according to current standard of care while in the ED and complete quality of life questionnaires in the ED and follow-up at 30 days.",[231,232],"Atrial Fibrillation (AF)","Atrial Flutter",[234,235,236,237],"Cardiac computed tomography angiography","Cardioversion","Atrial flutter","Atrial fibrillation","2026-06-08",{"date":240,"type":34},"2026-06-09",{"date":242,"type":34},"2025-06-15",{"date":244,"type":21},"2028-06-15",{"name":40,"class":41},3,{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":125,"phases":257,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":42},"100639327","phase-4-investigating-a-personalized-approach-to-anti-platelet-therapy-100639327","NCT07602257","Investigating a Personalized Approach to Anti-Platelet Therapy","Reassessment of Anti-Platelet Therapy Using an Individualized Strategy With Pharmacogenomics to Refine Anti-Platelet Drugs in Vulnerable Patients to Eliminate Thrombotic and Bleeding Complications - A Cluster Randomized Pilot Study","RAPID PREVENT","Inclusion Criteria:\n\n* Age \\>18 years old\n* Receiving PCI with stenting\n\nExclusion Criteria:\n\n* Inability to take ticagrelor\n* Inability to take clopidogrel\n* Not expected to survive \\>48hours\n* Not able to complete a buccal swab",{"count":256,"type":21},1760,[258],"PHASE4","RAPID PREVENT aims to identify if a personalized (targeted) anti-platelet strategy will reduce bleeding events when compared to the current standard anti-platelet therapy.",[261],"High Risk Bleeding",[263,264,265],"Thrombosis","bleeding complications","Anti-platelet therapy","2026-05-15",{"date":268,"type":34},"2026-05-22",{"date":270,"type":21},"2026-06-01",{"date":272,"type":21},"2029-12-28",{"name":40,"class":41},{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":125,"phases":284,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":301,"locationsCount":42},"100639181","study-of-feasibility-for-surgical-patients-undergoing-heart-surgery-with-the-mammary-arteries-reviewing-infection-occlusion-rates-and-pain-assessments-100639181","NCT07599553","Study of Feasibility for Surgical Patients Undergoing Heart Surgery With the Mammary Arteries: Reviewing Infection, Occlusion Rates and Pain Assessments.","Pilot Study for COMFORT Trial Comparative Outcomes of Mammary Artery Harvesting: Infection, Occlusion Rates and Thoracic Pain Assessment","COMFORT pilot","Inclusion Criteria:\n\n* Age 18 years or older\n* Undergoing isolated CABG surgery with median sternotomy and a planned LIMA-LAD graft.\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Non-sternotomy surgical approach (e.g., minimally invasive, thoracotomy)\n* Emergency surgery (defined as surgery required within 24 hours or presentation\n* History of prior ternotomy\n* Currently receiving systemic antibiotics or with an active bacterial infection at the time of surgery\n* History of chronic sternal pain prior to the index surgery.\n* Known left subclavian artery stenosis (\\>50%)\n* Previous radiation therapy to the chest\n* Known allergy or contraindication to iodinated contrast media that cannot be managed with premedication.\n* Estimated glomerular filtration rate (eGFR) \\\u003C30 ml\u002Fmin\u002F1.73m2 at baseline (relative contraindications to CTA contrast). The eGFR will be determined by each participating institution according to their standard practice.",{"count":283,"type":21},35,[154],"The Pilot study for the COMFORT Trial is a single centre trial to determine the feasibility of the full COMFORT Trial.\n\nThe main COMFORT Trial will be a multi-centre trial to investigate the coronary artery bypass grafting outcomes when harvesting the Left Internal Mammary Artery (LIMA) using a skeletonized approach (artery is isolated without the surrounding veins, fascia and nerves) compared to harvesting the LIMA using a non-skeletonized approach (artery is isolated with the surrounding veins, fascia and nerves). Harvesting the LIMA with the non-skeletonized approach is the standard technique. Participants will complete a Coronary Artery Tomography scan at 1 year to determine if the LIMA graft remains open. Follow up of the participants will continue until 2 years post surgery.",[287],"Graft Patency",[289,290,291,292,293,294],"bypass graft harvesting","skeletonized harvesting","non-skeletonized harvesting","CABG surgery","Left Internal Mammary Artery","LIMA","2026-05-14",{"date":297,"type":34},"2026-05-20",{"date":299,"type":21},"2026-06",{"date":114,"type":21},{"name":40,"class":41},{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":125,"phases":312,"briefSummary":313,"conditions":314,"keywords":318,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":42},"100570656","phase-3-targeting-vascular-inflammation-in-patients-with-community-acquired-pneumonia-100570656","NCT06710080","Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia","Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia (TIN_CAP): a Multi-centre, Prospective, Randomized Control Trial","TIN-CAP","Inclusion Criteria:\n\nPatients who have:\n\n1. Hospitalization with CAP (defined as pulmonary infiltration using chest imaging, in addition to other clinical symptoms including fever, cough, and sputum)\n2. age \\> 18 years;\n3. given informed consent.\n\nExclusion Criteria:\n\nPatients who have:\n\n1. history of cancer within the last 3 years (other than a successfully treated cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix).\n2. active inflammatory conditions (e.g. rheumatoid arthritis, chronic inflammatory bowel disease, SLE, systemic anti-inflammatory therapy (e.g. prednisone, methotrexate));\n3. pregnancy (all women of child bearing potential will have a negative BHCG test;\n4. breastfeeding;\n5. Women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception.\n6. Allergies to icosapent ethyl\n7. allergies to fish or shellfish\n8. glomerular filtration rate (GFR) \\\u003C50 ml\u002Fmin\u002F1.72m2 (excluded from CTA portion)\n9. unable to give informed consent;\n\nExclusion for CTA portion of the protocol:\n\nPatients with dye allergy will not undergo CTA but will have PET\u002FCT",{"count":311,"type":21},168,[127],"The goal of this clinical trial is to learn if icosapent ethyl (Vascepa) works to lessen the amount of inflammation in adults diagnosed with Community-Acquired Pneumonia (CAP). The main question it aims to answer is:\n\nWhat is the effect of taking Vascepa on inflammation in the arteries in patients with CAP? Researchers will compare the drug Vascepa to a placebo (a look-alike submstance that contains no drug) to see if Vascepa works to reduce inflammation in patients with CAP.\n\nParticipants wil:\n\n* take Vacscepa or a placebo twice a day for 6 months\n* Visit the clinic 3 times (baseline, 30 days, and 6 months) for checkups and tests",[315,316,317],"Inflammation","Community Acquired Pneumonia (CAP)","Inflammation Plaque, Atherosclerotic",[319,320,315,321],"Community-Acquired Infection","Plaque, atherosclerotic","Eicosapentaenoic Acid","2026-05-08",{"date":324,"type":34},"2026-05-11",{"date":326,"type":34},"2026-04-08",{"date":328,"type":21},"2027-06",{"name":40,"class":41},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":125,"phases":339,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":42},"100597506","phase-3-semaglutide-for-smoking-cessation-in-patients-with-diabetes-100597506","NCT07059377","Semaglutide for Smoking Cessation in Patients With Diabetes","Semaglutide for Smoking Cessation in Patients With Diabetes: A Pilot Randomized Controlled Trial","GLP1-SC","Inclusion Criteria:\n\n* Adults (18 years or older) with type 2 diabetes\n* Currently residing in Ontario\n* Smoke at least five cigarettes per day and willing to reduce or quit smoking within the next 6 months\n* Stable HbA1c ≥7.0% - 10% with no more than a 1% change over the last 3 to 6 months.\n* Have not used GLP-1 receptor agonists in the past six months.\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding individuals\n* Contraindication to NRT or GLP-1 RA.\n* Current daily use of NRT or a GLP1 RA.\n* Use of bupropion, cytisine, and varenicline within the last 7 days.\n* Use of a DPP-IV inhibitor within the last 7 days.\n* Initiation of a new diabetes medication within the last 3 months.\n* As per the product monograph, participants with the following diagnoses or disorders will be excluded;\n* Personal or family history of medullary thyroid cancer\n* Personal or family history of Multiple Endocrine Neoplasia syndrome type 2\n* Diabetic ketoacidosis\n* Type I diabetes\n* Acute pancreatitis or pancreatic cancer\n* Acute, chronic or end-stage renal failure\n* Tachyarrhythmias\n* Unable to engage in follow-up for any reason (for example an acute mental illness, cognitive impairment, unable to speak English or French).\n* Other conditions deemed by the study team to interfere with participation or outcomes in the opinion of the study investigator (for example acutely unwell, life expectancy less than 1 year).",{"count":152,"type":21},[127],"To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.",[342,343,344],"Diabetes Mellitus, Type 2","Nicotine Addiction","Tobacco Dependence","2026-05-05",{"date":324,"type":34},{"date":348,"type":34},"2026-02-13",{"date":350,"type":21},"2027-07",{"name":40,"class":41},{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":358,"eligibilityCriteria":359,"healthyVolunteers":360,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":363,"conditions":364,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":369,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":42},"100523107","florbetaben-for-imaging-of-vascular-amyloid-100523107","NCT06091319","Florbetaben for Imaging of Vascular Amyloid","Florbetaben for Imaging of Vascular Amyloid: Evaluation of Amyloid Inflammasome Imaging in Carotid and Coronary Arteries in Patients With Unstable Atherosclerosis- A Pilot Study","FERMATA","Inclusion Criteria:\n\n1. suffered a recent cardiovascular event (30-120 days post ACS (i.e. STEMI or NSTEMI) or TIA\u002Fstroke with ipsilateral large vessel atherosclerotic disease confirmed on US, CT or MRI;\n2. stable symptoms and hemodynamics;\n3. age \\>\u002F= 18 years;\n4. given informed consent.\n\nExclusion Criteria:\n\n1. a recent CV event likely to have been embolic in the opinion of the neurologist or cardiologist;\n2. severe LV dysfunction (EF\\\u003C30%);\n3. severe valve disease requiring intervention;\n4. decompensated heart failure;\n5. pregnancy (all women of child bearing potential will have a negative BHCG test;\n6. breastfeeding;\n7. women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception;.\n8. unable to give informed consent;.\n9. Florbetaben allergy;\n10. glomerular filtration rate (GFR) \\\u003C50 ml\u002Fmin\u002F1.72m2\n\nExclusion for CTA portion of the protocol: Patients with dye allergy, or those with GFR \\\u003C60, will not undergo CTA but will have PET\u002FCT.",true,{"count":362,"type":21},30,"The Primary Objective is to determine if a new nuclear tracer (named 18F-Florbetaben) used with nuclear imaging (PET imaging) can detect inflamed plaque in patients with recent ACS or stroke\u002FTIA.",[365,366,367,368],"Acute Coronary Syndrome","Stroke","Transient Ischemic Attack","Atherosclerosis of Artery",{"date":322,"type":34},{"date":371,"type":34},"2023-10-09",{"date":373,"type":21},"2026-08-01",{"name":40,"class":41},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":125,"phases":385,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":397,"locationsCount":42},"100472069","phase-2-canagliflozin-targeting-vascular-inflammation-100472069","NCT05427084","Canagliflozin Targeting Vascular Inflammation","Canagliflozin Targeting Vascular Inflammation: An Ottawa Imaging Study - A Pilot Study","CANTORSING","Inclusion Criteria:\n\n* 1\\) Stable CAD (over 60 days post-myocardial infarction).\n* 2\\) Diabetes\n* 3\\) given informed consent.\n\nExclusion Criteria:\n\n1. severe LV dysfunction (EF\\\u003C50%);\n2. decompensated heart failure;\n3. active infection (e.g. pneumonia, active skin infections, and on antibiotics);\n4. active inflammatory conditions (e.g. rheumatoid arthritis, chronic inflammatory bowel disease, SLE, systemic anti-inflammatory therapy (e.g. prednisone, methotrexate));\n5. pregnancy (all women of child bearing potential will have a negative BHCG test;\n6. breastfeeding;\n7. Women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception.\n8. glomerular filtration rate (GFR) \\\u003C50 ml\u002Fmin\u002F1.72m2;\n9. Use of p-glycoprotein inhibitor (e.g. cyclosporine, verapamil, or quinidine) or a strong CYP3A4 inhibitor (e.g. ritonavir, clarithromycin, or ketoconazole);\n10. Hemoglobin \\\u003C 105(women) \\\u003C110 (men) g\u002FL; WBC \\\u003C 3.0x 10(9)\u002FL, platelet count\\\u003C 110x 10(9)\u002FL;\n11. Patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease or with alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal.\n12. unable to give informed consent;",{"count":384,"type":21},24,[386,127],"PHASE2","CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs. placebo (control group) on the FDG aortic uptake in patients with stable CAD (over 60 days post-myocardial infarction) after a 6-month period of treatment. The investigators plan to enroll 8 patients in each arm (total sample size: 16 patients). Primary endpoint is the change in FDG aortic uptake between baseline and 6 months in each arm.",[389,390],"Diabetes Type 2","Coronary Artery Disease","2026-04-30",{"date":393,"type":34},"2026-05-06",{"date":395,"type":34},"2024-11-15",{"date":193,"type":21},{"name":40,"class":41},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":125,"phases":407,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":419,"leadSponsor":420,"locationsCount":4},"100611843","phase-3-pericardial-imaging-study-100611843","NCT07245849","Pericardial Imaging Study","Identifying Clinical, Serum, and Imaging Based Biomarkers Associated With High-Risk Phenotypes for Recurrent Pericarditis: A Prospective Cohort Study","Inclusion Criteria:\n\n1. History of recurrent pericarditis\\* (i.e. presentation of at lease 2nd episode of acute pericarditis).\n2. Age \\>\u002F= 18 years\n3. Given informed consent\n\n   * standard definitions will be used to define an episode of pericarditis. Pericarditis will be diagnosed by using available published criteria, which includes typical pericardial chest pain, pericardial friction rubs, widespread ST segment elevation or PR-segment depression that was not previously reported and new or worsening pericardial effusion on echocardiography. A clinical diagnosis of acute pericarditis will be made when at least 3 of these criteria are present.\n\nExclusion Criteria:\n\n1. severe valve disease requiring intervention\n2. claustrophobia that precludes FDG\u002FPET or CMR imaging\n3. pregnancy (all women of child bearing potential will have a negative BHCG test)\n4. breastfeeding\n5. glomerular filtration rate (GFR) \\\u003C50 m\u002Fmin\u002F1.72m2",{"count":406,"type":21},44,[127],"The pericardium is a thin, double-layered sac around the heart that helps reduce friction as the heart moves. When this sac gets inflamed, it is called pericarditis, which can cause serious health problems and even be life-threatening. Pericarditis often comes back after the first episode. About 10-30% of people will have it again, and half of those will have it multiple times. Although there are treatments available, they are costly and not often used because we can't predict who best to use them on. Finding a way to predict which patients would benefit from these treatments could help reduce the burden on patients and the healthcare system.\n\nThis study will use a test called an 18F-FDG PET\u002FCT with CTA Scan (18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) with computer tomography angiography (CTA)) to measure inflammation in the pericardium.\n\nThe purpose of the study is to create easy-to-use tools for doctors to identify people at high risk of pericarditis coming back, so they can get advanced treatment early. This study will help fill knowledge gaps about key predictors like clinical signs, blood tests, and imaging results.",[410],"Pericarditis",[412,413,414],"PET","pericarditis","FDG","2026-04-29",{"date":417,"type":34},"2026-05-01",{"date":193,"type":21},{"date":350,"type":21},{"name":40,"class":41},{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":125,"phases":429,"briefSummary":430,"conditions":431,"keywords":432,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":436,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":169},"100567637","standardized-goal-directed-vs-self-directed-valsalva-maneuver-for-the-assessment-of-patent-foramen-ovale-100567637","NCT06670781","Standardized Goal-Directed vs. Self-Directed Valsalva Maneuver for the Assessment of Patent Foramen Ovale","Inclusion Criteria:\n\n* Patients referred for a clinically indicated TTE and bubble study\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Inability to insert an IV line\n* Inability to perform a Self-Directed Valsalva maneuver\n* Patient wishing to keep his mask on",{"count":428,"type":21},488,[154],"Ischemic stroke represents a major public health issue, leading to significant disabilities and deaths worldwide. When no clear cause for stroke is found following a comprehensive cardiovascular evaluation (no atrial fibrillation, cardiac masses, or atherosclerosis) i.e. cryptogenic stroke, it is recommended to search for a patent foramen ovale (PFO), especially in young patients. It is estimated that cryptogenic stroke accounts for 30% to 40% of ischemic strokes. Transthoracic echocardiography (TTE) with bubble study at rest and during Valsalva maneuver is the reference method for the diagnosis of PFO. The treatment of PFO using a closure device has demonstrated a significant reduction in recurrent stroke events in patients with PFO and cryptogenic stroke. The Valsalva maneuver is currently achieved using self-directed maneuver i.e. patients are instructed to ''bear down'' or ''strain as if attempting to move your bowels.'' These instructions are subjective and depend largely on individuals understanding and effort. A Goal-Directed Valsalva Maneuver using a manometer has been shown to be a more reproducible way to perform the Valsalva achieving more sensitivity in different settings such as hypertrophic cardiomyopathy but its incremental diagnostic value for the detection of PFO has not been yet evaluated.\n\nThe aim of the present study is to compare the sensibility and specificity of two methods of Valsalva maneuver for the detection of PFO. We hypothesize that Goal-Directed Valsalva Maneuver will significantly increase the detection rate of PFO compared to Self-Directed Valsalva Maneuver.",[366],[433,366,434,435],"Bubble study","Echocardiography","patent foramen ovale",{"date":391,"type":34},{"date":438,"type":34},"2025-01-30",{"date":440,"type":21},"2026-10",{"name":40,"class":41},{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":446,"acronym":447,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":125,"phases":451,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":457,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":42},"100558182","left-atrial-monitoring-in-patients-before-and-after-mitral-surgery---lambda-study-100558182","NCT06547788","LEFT ATRIAL MONITORING IN PATIENTS BEFORE AND AFTER MITRAL SURGERY - LAMBDA STUDY","LAMBDA","Inclusion Criteria:\n\n* Patients ≥18 years of age\n* Severe (4+) symptomatic Carpentier Type II MR due to degenerative disease\n* Planned surgical mitral valve repair\n* Right-to-left atrial pressure gradient ≥ 5 mmHg at baseline\n* Pulmonary vascular resistance ≤ 4 Wood units\n\nExclusion Criteria:\n\n* Secondary causes of MR and mixed mitral valve disease\n* Infective endocarditis within 30-days\n* Any prior mitral valve intervention\n* Need for emergency intervention or surgery\n* Left ventricular ejection fraction 2+",{"count":450,"type":21},50,[154],"Mitral valve leakage, or mitral regurgitation (MR), is associated with heart failure symptoms including shortness of breath, fatigue, irregular heart rate. When left untreated, it may cause death. Patients with MR can be divided in two broad groups: those with primary MR, caused by disease of the mitral valve structures, and those with secondary MR, due to dilation of the heart chambers. Our study focuses on patients with primary MR.\n\nThe standard treatment for severe symptomatic primary MR is mitral valve surgery, a type of open-heart surgery. The outcomes following this procedure are excellent, however, a subset of patients continue to experience heart failure symptoms after surgery due to very high pressures in the heart, more specifically in the left atrium, which is one of the four heart chambers. This is called functional mitral stenosis (FMS).\n\nPrevious studies have shown that creating a small opening between the left and right atria can help relieve the pressure inside the left atrium. We would like to determine whether creating this opening between the two atria at the time of mitral valve surgery can help prevent FMS. To answer this question, we will study two groups of patients who need mitral valve surgery for primary MR. The first group will undergo mitral valve surgery, along with the creation of the opening between the two atria. The second group will undergo mitral valve surgery alone. We will then compare the outcomes between both groups, namely with regards to their heart failure symptoms after open-heart surgery.",[454,455,456],"Mitral Regurgitation","Mitral Valve Disease","Heart Failure",{"date":393,"type":34},{"date":459,"type":21},"2026-09-30",{"date":461,"type":21},"2030-01-31",{"name":40,"class":41},{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":125,"phases":473,"briefSummary":474,"conditions":475,"keywords":479,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":484,"leadSponsor":486,"locationsCount":4},"100547252","phase-2-midodrine-in-heart-failure-with-reduced-ejection-fraction-with-hypotension-100547252","NCT06405555","Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension","Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension: A Pilot, Open-label, Randomized Controlled Trial","MIDOH-HF-P","Inclusion Criteria:\n\n* Adults \\>= 18 years of age.\n* LVEF \\\u003C= 40 % within the last 3 months as determined by any one of: Transthoracic echocardiogram, transesophageal echocardiogram, cardiac magnetic resonance imaging, MUGA scan, angiogram with left ventriculogram.\n* AHA\u002FACC Stage B or C Heart Failure\n* Hospitalized patients in the ward setting OR in the cardiac intensive care unit (who are \\>= 48 hours after their last dose of vasopressor or inotrope).\n* Seated upright or supine SBP \\\u003C= 100 mmHg on two or more consecutive BP measurements separated by at least 8 hours\n\nExclusion Criteria:\n\n* Patient OR substitute decision-maker (SDM) unwilling or unable to provide informed consent\n* Documented allergy or intolerance to midodrine\n* Treatment for active infection (either documented infection or empiric treatment) with antimicrobials at the time of recruitment.\n* Current use OR any use within the last 48 hours of an intravenous inotrope or vasopressor medication OR the need for IV inotrope or vasoproessor use to treat hypotension\n* Patient within 72 hours of an acute coronary syndrome.\n* Heart transplant recipient.\n* Presence of temporary or durable mechanical circulatory support device.\n* Severe valvular disease expected to be intervened upon during the incident hospitalization.\n* Hyperkalemia \\>= 5.5 mmol\u002FL.\n* Baseline eGFR (as calculated by the CKD-EPI method) \\\u003C= 20 mL\u002Fmin\u002F1.73 m2 as measured within the last 3 months.\n* A treatable cause for hypotension, including but not limited to: hypovolemia (eg. Bleeding, overdiuresis, poor oral intake), obstructive shock, sepsis, adrenal insufficiency.\n* Clinical diagnosis of ongoing cardiogenic shock, or diagnosed as defined in SHOCK trial: sBP \\\u003C= 90 mmHg with evidence of end-organ hypoperfusion (cool extremities, urine output \\\u003C 30 mL\u002Fhr, HR \\> 60 bpm, or elevated lactate \\>=3.5 mmol\u002FL), invasive hemodynamic measurements (if available) of CI \\\u003C= 2.2 L\u002Fmin\u002Fm2 and a pulmonary capillary wedge pressure (PCWP) of \\>=15 mmHg.\n* Pregnant patient.\n* Anticipated patient discharge in less than two days from enrolment (ie. less than 6 anticipated doses of midodrine, if randomized to treatment\u002Fintervention arm).\n* Acute brain pathology (including, but not limited to intracranial hemorrhage or hematoma) in which most-responsible clinician deems it unsafe to augment blood pressure.\n* Untreated thyrotoxicosis\n* Acute or acute on chronic liver failure\n* Patient unable to take oral medications\n* Bradycardia with resting heart rate less than 50 beats per minute.\n* Patients on an equivalent dose of Lasix \\>= 80 mg IV BID",{"count":472,"type":21},56,[386,127],"The evidence-based pharmacologic treatments available for patients with heart failure with reduced ejection fraction (HFrEF) has been established over the last few decades of cardiovascular research. These treatments, termed Foundational Guideline-Directed-Medical Therapies (GDMT), prolong patient life, improve patient-reported symptoms, and reduce hospitalizations for heart failure. A direct effect of most medication classes encompassed within GDMT is the reduction in blood pressure due to their mechanisms of action. In addition, as patients with HFrEF become more advanced in their disease, a significant proportion develop hypotension related to pump failure and autonomic dysfunction, amongst other possible mechanisms. As a result, a significant proportion of HFrEF patients are not optimized on GDMT with hypotension as their limiting barrier that would otherwise have served to improve their heart function, heart failure symptoms, and mortality. Currently, there does not exist any evidence-based strategies to address the problem of hypotension in HFrEF patients who are not optimized on GDMT.\n\nMidodrine is an alpha-adrenergic agonist (α1-AR) that exerts its effects on peripheral venous and arteriolar vasculature to increase blood pressure. This medication has been used off-label by some clinicians in the hypotensive HFrEF population to increase blood pressure and has been reported to have beneficial effects in improving GDMT utilization as well as increasing left ventricular ejection fraction (LVEF) in published case reports\u002Fcase series. There does not exist any randomized prospective data on the use of midodrine in the hypotensive HFrEF population. The investigators' objective is to complete the first open-label, randomized control trial of midodrine in the hypotensive HFrEF population to demonstrate feasibility in performing a trial in this patient population and to show efficacy in increasing blood pressure without associated harm. The results of this trial will be used as the foundation and rationale for future studies assessing the impact of midodrine use on GDMT utilization as well as hard cardiovascular outcomes in the hypotensive HFrEF population, including hospitalizations for heart failure and mortality.",[476,477,478],"Heart Failure With Reduced Ejection Fraction","Hypotension","LV Dysfunction",[456,480,481],"GDMT","Midodrine",{"date":391,"type":34},{"date":270,"type":21},{"date":485,"type":21},"2028-06-01",{"name":40,"class":41},{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":125,"phases":496,"briefSummary":497,"conditions":498,"keywords":500,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":508},"100522966","mariner-trial-multiparametric-cardiac-pet-for-cav-surveillance-after-heart-transplantation-100522966","NCT06089486","MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation","Multiparametric Cardiac Positron Emission Tomography for Cardiac Allograft Vasculopathy Surveillance After Heart Transplantation","Inclusion Criteria:\n\n1. Post heart transplant 2-10 years.\n2. Age ≥18 years.\n3. Able to provide informed consent.\n\nExclusion Criteria:\n\n1. Contraindication to dipyridamole due to severe aortic stenosis.\n2. Contraindication to dipyridamole due to 2:1 or greater AV block without pacemaker.\n3. Contraindication to dipyridamole due to severe bronchospasm.\n4. Unable to undergo coronary angiography due to allergy to iodinated contrast.\n5. Unable to undergo coronary angiography due to glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2. for non-dialysis patients as determined by local laboratory analysis.\n6. Unable to undergo coronary angiography due to unsuitable vascular access.\n7. Treated rejection ≤1-month.\n8. Unstable angina or MI ≤7 days.",{"count":495,"type":21},576,[154],"Cardiac allograft vasculopathy (CAV) is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. Surveillance for CAV is vital; however an ideal approach has not been established. The goal of this study is to assess whether noninvasive positron emission tomography (PET) based surveillance is non-inferior to invasive coronary angiography (ICA) surveillance.",[499],"Cardiac Allograft Vasculopathy",[501],"Heart Transplant",{"date":393,"type":34},{"date":504,"type":34},"2024-01-08",{"date":506,"type":21},"2029-03",{"name":40,"class":41},5,{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":125,"phases":518,"briefSummary":519,"conditions":520,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":522,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":528},"100462166","transcatheter-mitral-valve-repair-for-inotrope-dependent-cardiogenic-shock-100462166","NCT05298124","Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock","MINOS","Inclusion Criteria:\n\n1. Participants or substitute decision maker is able and willing to provide written informed consent\n2. Age ≥ 18 years\n3. SCAI stage C or D cardiogenic shock with persistent inotrope\u002Fvasopressor\u002Fnon-durable mechanical support or unable to wean ventilatory support due to pulmonary edema for 24 hours prior to randomization\n4. Greater than or equal to 3+ MR as determined by a study center's transesophageal echocardiogram (TEE)\n5. In the opinion of the study center's heart team the participant is anatomically eligible for TMVr with the potential to achieve \\\u003C3+ MR\n\nExclusion Criteria:\n\n1. Unwilling or unable to obtain informed consent from the participant or substitute decision maker\n2. Revascularization of coronary artery disease performed in the 48 hours prior to randomization\n3. If the mechanism of MR is deemed to be degenerative, in the opinion of the heart team the participant is eligible for surgical intervention\n4. Prior mitral valve leaflet surgery or implanted mitral valve prosthesis (excluding ring)\n5. Echocardiographic evidence of left sided intracardiac mass or thrombus\n6. Diagnosis of active infective endocarditis\n7. Transesophageal echocardiogram is contraindicated\n8. Mitral valve anatomy deemed contraindication to TMVr implantation that cannot be addressed procedurally as determined by the study center's heart team\n9. Any aortic valve disease greater than moderate in severity\n10. A known hypersensitivity or contraindication to procedure medications which cannot be adequately managed medically\n11. Out of hospital cardiac arrest or in-hospital cardiac arrest without documented neurologic recovery\n12. Plan for durable mechanical circulatory support implantation prior to TMVr\n13. In the opinion of the treating team, there is a significant comorbidity that would limit life expectancy in hospital\n14. Pregnant or planning to become pregnant in the next 6 months.",{"count":517,"type":21},144,[154],"Mitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurgitation in the setting of cardiogenic shock; however, there remains a lack of randomized clinical data to support the use of TEER in cardiogenic shock.\n\nThis study will be a multicenter, open-label, randomized-controlled trial with two study arms: medical therapy and TEER. Patients admitted to the Cardiac Intensive Care Unit (CICU), Cardiac Surgery Intensive Care Unit (CSICU) or Intensive Care Units (ICU) at participating centers will be recruited.\n\nThe study aims to answer the question: \"Does TEER in patients with SCAI stage C or D cardiogenic with concomitant moderate or greater mitral regurgitation improve outcomes as compared to medical therapy?\"\n\nThe study hypothesis is that TEER will lead to an overall improvement in the composite outcome as compared to the medical therapy arm.",[521,454],"Cardiogenic Shock",{"date":393,"type":34},{"date":524,"type":34},"2022-05-26",{"date":526,"type":21},"2028-05",{"name":40,"class":41},4,{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":125,"phases":538,"briefSummary":539,"conditions":540,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":541,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":545,"locationsCount":246},"100421608","phase-3-aerial-trial-antiplatelet-therapy-in-heart-transplantation-100421608","NCT04770012","AERIAL Trial: Antiplatelet Therapy in Heart Transplantation","Early Initiation of Antiplatelet ThERapy In HeArt TranspLantation: AERIAL Trial","Inclusion Criteria:\n\n1. Heart transplant\n2. Age ≥18 years\n3. Able to provide informed consent\n\nExclusion Criteria:\n\n1. Allergy or known intolerance to aspirin\n2. Allergy or known intolerance to clopidogrel\n3. Intracranial hemorrhage ≤14 days\n4. Bleeding disorder\n5. Platelet count \\\u003C50 x 109\u002FL\n6. History of aspirin related gastrointestinal bleeding or ulcers\n7. Non-cardiac indication for antiplatelet therapy\n8. Anticoagulation \\>3 months\n9. Allergy to iodinated contrast\n10. Unable to undergo coronary angiography due to glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2 for non-dialysis patients\n11. Unable to undergo coronary angiography due to unsuitable vascular access\n12. Combined solid organ transplantation.",{"count":537,"type":21},135,[127],"Cardiac allograft vasculopathy is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. The research team is investigating whether early antiplatelet therapy post heart transplant can prevent the development of CAV. This study will determine the feasibility of a large multicenter randomized placebo-controlled trial to answer this question.",[499,501],{"date":393,"type":34},{"date":543,"type":34},"2021-06-28",{"date":506,"type":21},{"name":40,"class":41},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":550,"acronym":551,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":125,"phases":555,"briefSummary":556,"conditions":557,"keywords":560,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":567,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":528},"100375023","the-initiate-study-initiating-nicotine-dependence-treatment-for-smokers-admitted-to-emergency-departments-100375023","NCT04163081","The INITIATE Study: Initiating Nicotine Dependence Treatment for Smokers Admitted to Emergency Departments","INITIATE","Inclusion Criteria:\n\n* Current daily smoker (smokes ≥ 5 cigarettes per day);\n* ≥ 18 years of age (the age of majority in Ontario);\n* For ED sites only, assigned a CTAS level of 2-5 (emergent to non-urgent);\n* Able to read and understand English or French;\n* Resides in Ontario and eligible for Ontario Health Insurance Plan (to permit linkage with administrative data housed at the Institute for Clinical Evaluative Sciences \\[ICES\\]);\n* Available and willing to participate in follow-up assessments over the next 12 months;\n* Has access to a telephone or computer;\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Currently participating in this or another smoking cessation study;\n* For ED sites only, assigned a CTAS level of 1 (resuscitation - the most seriously ill patients with highest likelihood of hospital admission) or in psychiatric emergency unit;\n* Pregnant, planning to become pregnant over the next year, or breastfeeding;\n* Has morbid illness which will prevent completion of 26-week follow-up (e.g., receiving palliative care);\n* In the opinion of the attending physician, manifests acute physical and\u002For psychiatric illness or has cognitive impairment that would preclude participation in\u002Fbenefit from the intervention.\n* Scheduled for a known elected surgery, procedure, or future hospitalization during the study period.",{"count":554,"type":21},1208,[154],"The INITIATE Study is a randomized controlled trial that is testing an intervention designed to increase long-term abstinence among tobacco smokers seen in emergency departments (ED) and other high-volume hospital and community ambulatory care settings. The intervention includes a behavioural incentive and tailored follow-up support on long-term smoking abstinence, health, healthcare utilization, and cost. Tobacco-related illnesses cost the healthcare system millions each year. Quitting smoking improves smoking-related outcomes, like the onset or management of heart disease, stroke, lung diseases, and several cancers. There are approximately 16 million visits to Canadian EDs each year; an estimated 3-4 million of these involve smokers. Effective quit smoking interventions exist, but are underutilized. Few hospital EDs, community healthcare centers, and other inpatient and outpatient clinics in Canada offer tobacco-use interventions. In order for clinicians to offer quit smoking support, interventions need to be simple given the realities of these high-volume environments. Considering that stopping smoking improves health outcomes, that tobacco-use is an important cause of preventable ED use, and the volume of smokers, Canadian EDs and other high-volume hospital and community ambulatory care settings are a missed opportunity in the initiation of quit smoking support. Our intervention has been designed to optimize uptake and smoking abstinence by including the most effective evidence-based behavioural and drug-related approaches, removing specific barriers and challenges that smokers face when trying to quit (e.g., affordability, low confidence and motivation), while packaging the intervention in a quick-to-initiate manner, making it ideal for fast-paced, complex environments.",[558,559],"Nicotine Dependence, Cigarettes","Nicotine Withdrawal",[561,562,563,564,565,566],"Nicotine Replacement Therapy","Emergency Department","Nicotine Dependence","Tobacco Abstinence","Tobacco Treatment","Cigarette",{"date":393,"type":34},{"date":569,"type":34},"2022-04-19",{"date":571,"type":21},"2027-03",{"name":40,"class":41},{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":579,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":125,"phases":583,"briefSummary":584,"conditions":585,"keywords":587,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":590,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":42},"100293750","biomarker-guided-discharge-of-heart-failure-patients-100293750","NCT03103932","Biomarker Guided Discharge of Heart Failure Patients","BiomarkeR cAndidates to Guide Discharge of Patients Admitted to Hospital With heARt Failure","RADAR","Inclusion Criteria:\n\n* Patients admitted to hospital with a primary diagnosis of acute decompensated heart failure, compatible with the modified Framingham criteria\n\nExclusion Criteria:\n\n* Patient unable to provide blood samples or cannot participate in follow-up\n* Patient with end stage organ failure\n\n  * Kidney: creatinine \\>350 μmol\u002FL or Estimated GFR ≤15 ml\u002Fmin\n  * Liver dysfunction: liver function test \\>2.5 times normal\n  * Lungs: pulmonary FEV1\\\u003C50% predicted\n* Patient requiring intubation\n* Patient with an admission NTproBNP measurement of \\>30,000 pg\u002Fml\n* Patient listed for heart transplant, or admitted specifically for transplant workup\n* Patient in cardiogenic shock\n* Patient with life expectancy of less than 6 months, or has major co-morbidities such as new stroke, cancer, pneumonia, or other serious life threatening illness\n* Patient with conditions that will make it difficult to discharge from hospital such as a fall or waiting for a long term care bed\n* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the trial, or may bias the result of the trial, or the patient's ability to participate in the trial\n* Patient who has participated in another research trial involving an investigational product in the past 30 days",{"count":582,"type":21},750,[154],"This is a multi-centre, single blind, randomized study. Patients admitted to hospital with acute decompensated heart failure will be randomized to biomarker guided discharge algorithm vs usual care in a 2:1 ratio. NTproBNP and other biomarkers will be measured within 24 hours of admission. The NTproBNP results will be used to further stratify participants randomized to the biomarker guided group into lower and medium to higher risk pathways. Biomarkers will be repeated after 2-3 days and again prior to discharge. Specific care pathways will be followed for each of the lower risk and medium-higher risk groups. Biomarkers will be repeated 30 days post discharge. Participants will be followed with a phone call at 3 months and return for a follow up visit at 6 months post discharge for outcome evaluation.",[586],"Heart Failure; With Decompensation",[28,588,589],"heart failure","hospital admission",{"date":393,"type":34},{"date":592,"type":34},"2017-08-26",{"date":594,"type":21},"2026-12-30",{"name":40,"class":41},{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":600,"acronym":601,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":125,"phases":605,"briefSummary":606,"conditions":607,"keywords":609,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":618,"locationsCount":246},"100459843","phase-4-capital-doremi-2-inotrope-versus-placebo-therapy-for-cardiogenic-shock-100459843","NCT05267886","CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock","DOREMI-2","Inclusion Criteria:\n\n* Adult patients ≥ 18 years of age admitted to an intensive care unit\n* SCAI class C or D cardiogenic shock\n\nExclusion Criteria:\n\n* Unwilling or unable to obtain informed consent by the participant or substitute decision maker\n* Patients who are currently pregnant or breast-feeding\n* Patients presenting with an out-of-hospital cardiac arrest (OHCA)\n* Administration of milrinone or dobutamine in the 24 hours preceding anticipated randomization\n* Severe obstructive valvular lesions, including aortic stenosis and\u002For mitral stenosis\n* Dynamic left ventricular outflow tract obstruction",{"count":604,"type":21},346,[258],"The investigators are interested in determining if there is a meaningful benefit from the use of medications purported to increase the pumping function of the heart (i.e. inotropes) among critically ill patients admitted to the Cardiac Intensive Care Unit (CICU). To do this, the investigators will conduct a multi-centre, double blind, randomized control trial with patients who are deemed to require these medications by their treating physician to one of the two most commonly used agents in Canada (Milrinone or Dobutamine) or placebo. Each patient will be closely monitored by their healthcare team. The dose of medication will be adjusted according to each patients' clinical status. After 12 hours, the participants will move to open label treatment and any continued use of inotropes will be at the discretion of their treating physician.",[608],"Shock, Cardiogenic",[610,611,612],"cardiogenic","shock","inotrope","2026-04-27",{"date":417,"type":34},{"date":616,"type":34},"2022-03-05",{"date":193,"type":21},{"name":40,"class":41},""]